Keppra Shortage: What Providers and Prescribers Need to Know in 2026

Levetiracetam (Keppra) is a cornerstone of modern epilepsy management, with more than 6 million U.S. prescriptions annually and use across a wide spectrum of seizure types and patient populations. While the drug's generic availability since 2008 has generally supported stable supply, availability challenges — both nationally and at the pharmacy level — have created clinical headaches for prescribers and their patients. This guide summarizes what neurologists and prescribers need to know about levetiracetam availability in 2026.

Current Supply Status (Early 2026)

As of early 2026, levetiracetam is not on the FDA's official drug shortage list. Multiple generic manufacturers supply the U.S. market with immediate-release tablets in all four strengths (250 mg, 500 mg, 750 mg, 1000 mg), as well as oral solution (100 mg/mL) and extended-release (XR) formulations. Brand Keppra and brand Keppra XR continue to be manufactured by UCB Pharmaceuticals.

Despite this nominally stable national picture, clinicians should be aware that:

Retail pharmacies typically stock only one generic manufacturer's product at any given time. If that manufacturer experiences a production issue, pharmacy stock is depleted regardless of national supply adequacy.

Keppra XR is stocked less consistently than immediate-release tablets, with smaller pharmacy inventories given lower prescription volume.

A 2024 patient survey (UK) found that 62.8% of epilepsy patients had experienced difficulty obtaining levetiracetam — highlighting a meaningful gap between official shortage declarations and real-world patient experience.

Clinical Risks When Patients Can't Access Levetiracetam

The primary risk when patients cannot fill their levetiracetam prescription is breakthrough seizures. Abrupt discontinuation or dose reduction of any anti-seizure medication (ASM) can lower seizure threshold and provoke seizures — including generalized tonic-clonic seizures — in patients who may have been seizure-free for months or years.

Breakthrough seizures carry implications beyond the immediate medical event: loss of driving privileges, fall and injury risk, workplace safety concerns, and significant patient anxiety and quality-of-life impact. Prescribers should treat levetiracetam access problems as urgent clinical issues, not administrative inconveniences.

Practical Strategies to Manage Availability Gaps

When a patient cannot find their prescribed levetiracetam formulation, consider the following in-class solutions before resorting to therapeutic substitution:

Equivalent dose using available strengths: For example, if 750 mg tablets are unavailable, prescribe 500 mg + 250 mg or one 500 mg + one 250 mg combination to reach the same total dose.

Oral solution: The 100 mg/mL grape-flavored oral solution is often available when tablets are not. It is bioequivalent and can be used in adults as well as pediatric patients.

IR to XR conversion: If XR is available but IR is not, or vice versa: immediate-release is dosed twice daily; extended-release is dosed once daily. Total daily dose should remain the same. Confirm with the package insert for conversion guidance.

Direct pharmacy outreach: Your office contacting a pharmacy on the patient's behalf is often the fastest solution. A quick call from your staff can locate stock in 15 minutes.

When Therapeutic Substitution Is Necessary: Alternatives to Consider

If a patient cannot access any levetiracetam formulation and you need to bridge with another ASM, consider the following based on seizure type:

Brivaracetam (Briviact): Same SV2A mechanism; 15–30× higher SV2A affinity; fewer psychiatric adverse effects; approved for focal-onset seizures. Can be converted from levetiracetam at approximately 1:1 mg ratio at the lower end (e.g., 1000 mg/day levetiracetam ≈ 100 mg/day brivaracetam). Brand-only; cost may be a barrier.

Lamotrigine (Lamictal): Appropriate for focal-onset and generalized seizures. Broad-spectrum efficacy. Requires slow titration (risk of SJS with rapid uptitration); generic available. Not appropriate for acute/immediate switching.

Valproate (Depakote/Depakene): First-line for generalized epilepsy including JME. Significant teratogenic risk; contraindicated in pregnancy and women of childbearing potential without adequate contraception. Requires blood level monitoring.

Oxcarbazepine (Trileptal): Appropriate for focal-onset seizures specifically. Sodium channel blocker; good tolerability; generic available. Not recommended for primary generalized or myoclonic seizures.

Key Prescribing Considerations Specific to Levetiracetam

Renal dosing: Levetiracetam is primarily renally eliminated (~66% unchanged). Dose adjustment is required for CrCl <80 mL/min. Supplemental doses needed after hemodialysis.

Pregnancy monitoring: Plasma levels of levetiracetam decrease throughout pregnancy (more pronounced in the third trimester). Monitor levels closely and adjust dose as needed. Levetiracetam is considered one of the safer ASMs in pregnancy.

Psychiatric monitoring: Up to 13% of adults and 38% of pediatric patients experience behavioral symptoms. Monitor for aggression, depression, irritability, and suicidal ideation, especially in the first weeks of therapy.

DRESS alert: In December 2023, the FDA issued an alert that levetiracetam can cause DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms), a potentially life-threatening hypersensitivity reaction. Educate patients to report rash, fever, and systemic symptoms immediately.

Tools to Help Your Patients Find Levetiracetam

medfinder for Providers (medfinder.com/providers) allows you to refer patients to a service that calls pharmacies in their area to check levetiracetam stock and reports back with which pharmacies have it available. This removes the burden from your staff of making dozens of pharmacy calls and gives patients actionable, near-real-time availability data.

For a patient-facing version of this shortage update, see our Keppra shortage update for patients — feel free to share this with your patients or direct them to medfinder.com.